Earnings Call Summary | BioNTech(BNTX.US) Q1 2024 Earnings Conference
Earnings Call Summary | BioNTech(BNTX.US) Q1 2024 Earnings Conference
The following is a summary of the BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript:
以下是BioNTech SE（BNTX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BioNTech reported Q1 2024 total revenues of approximately EUR 188 million, predominantly driven by their COVID-19 vaccine sales.
They reported a net loss for this quarter of EUR 315 million, compared to a net profit of approximately EUR 502 million for Q1 of 2023.
BioNTech reported a loss per share of EUR 1.31 for Q1 2024, compared to a profit per share of EUR 2.05 for Q1 2023.
BioNTech expects to recognize approximately 90% of its full-year revenues in the last months of 2024, mostly in Q4.
BioNTech 報告稱，2024 年第一季度總收入約爲 1.88 億歐元，主要受其 COVID-19 疫苗銷售的推動。
他們報告本季度的淨虧損爲3.15億歐元，而2023年第一季度的淨利潤約爲5.02億歐元。
BioNTech報告稱，2024年第一季度的每股虧損爲1.31歐元，而2023年第一季度的每股盈利爲2.05歐元。
BioNTech預計將在2024年最後幾個月確認其全年收入的約90％，主要是在第四季度。
Business Progress:
業務進展：
Undergoing a transformative period with the goal of progressing various drug candidates into late-stage development and registrational trials.
Dosed the first patient in a Phase 3 clinical trial for drug candidate BNT323, aimed at treating metastatic breast cancer.
Preparing to introduce a new variant-adapted COVID-19 vaccine and investing in a COVID-19 flu combination vaccine.
Plans to increase the number of potential pivotal trials to 10 or more by 2024, focusing on unmet medical needs.
Transitioning to a global multi-product company and developing an oncology organization to support this.
Significant investment in their mRNA platform approaches, which serve as core capabilities.
Working in partnership with Pfizer on variant-adapted COVID-19 vaccines.
Anticipates multiple oncology products reaching the market by 2026 onwards and intends to accelerate investment in several ongoing and upcoming clinical trials.
Secured breakthrough designation in endometrial cancer work, with pivotal data expected in the second half of next year.
正在經歷一個變革時期，目標是將各種候選藥物推進到後期開發和註冊試驗。
在旨在治療轉移性乳腺癌的候選藥物 BNT323 的 3 期臨床試驗中爲第一位患者服藥。
準備推出一種適應變體的新型 COVID-19 疫苗，並投資一種 COVID-19 流感聯合疫苗。
計劃到2024年將潛在的關鍵試驗數量增加到10項或更多，重點關注未滿足的醫療需求。
過渡到一家全球多產品公司，並發展一個腫瘤組織來支持這一點。
對他們的mRNA平台方法進行了大量投資，這些方法是核心能力。
與輝瑞合作開發適應變體的 COVID-19 疫苗。
預計到2026年將有多種腫瘤學產品上市，並打算加快對幾項正在進行和即將進行的臨床試驗的投資。
獲得子宮內膜癌研究的突破性認定，關鍵數據預計將於明年下半年公佈。
More details: BioNTech IR
更多詳情： BioNTech IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。